NEW YORK–(BUSINESS WIRE)–Oligomerix, Inc., a privately held company focused on therapeutics targeting tau for Alzheimer’s disease similar dementias, which is also currently seeking strategic partners to support the acceleration and advancement of those programs, has appointed Robert Foerster as Chief Financial Officer.
Foerster joins Oligomerix with significant financial, strategic and operational experience in the life science industry, Oligomerix said.
“We are very pleased to have Robert join our team at Oligomerix. He will bring important financial experience to our business as we continue to progress towards IND filing and Phase 1 clinical studies for our small molecule inhibitor of tau self-association,” said James Moe, President and CEO of Oligomerix.
Foerster said: “Oligomerix has hit significant milestones, most recently demonstrating that its small molecule can inhibit the initial steps of tau oligomer formation and reduce the subsequent formation of larger tau aggregates in vivo in models of AD and frontotemporal dementia.”
I’m excited to bring my experience in biopharmaceutical financial strategy and business development to a dynamic leadership team as the company advances towards starting clinical trials in 2021,” he added.
About Oligomerix’s Lead Program
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association and targets the beginning of the tau aggregation cascade. The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach. In vivo proof-of-concept studies demonstrated compound efficacy in two transgenic mouse models with tau pathology representative of AD and frontotemporal dementia. In a study recently published in the Journal of Alzheimer’s Disease, Oligomerix and the Feinstein Institutes for Medical Research reported that the compound inhibited hippocampal self-associated tau in the htau mouse model of tauopathy which expresses the six CNS isoforms of the human tau protein. Preclinical safety studies are underway with a lead compound. The lead compound is being developed with an accompanying novel biomarker.
